產(chǎn)品搜索
相關(guān)文章
- 拯救偏頭痛!CGRP及其受體拮抗劑研究進展
- ATCC細(xì)胞株的特殊性質(zhì)或標(biāo)志必須在整個培養(yǎng)期間始終存在
- 【連載-企業(yè)參考品】 前列腺癌的診斷參考品的選擇
- KIR3DL3/HHLA2細(xì)胞篩選模型
- 重磅!科學(xué)家成功利用免疫細(xì)胞運輸抗癌藥物至腫瘤靶點
- CYP1A1基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- ANG TIE2:重塑千億血管靶向治療市場,“血管-免疫”協(xié)同治療革命
- 黃金賽道——CDH17靶點
- 免疫治療的下一個靶標(biāo):腫瘤相關(guān)巨噬細(xì)胞?
- IHC第三方質(zhì)控品——病理質(zhì)控基石,精準(zhǔn)診斷起點
聯(lián)系我們
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73284c-Kit W557_K558del-T670I/BaF3

- 詳細(xì)內(nèi)容
CBP73284 | |
I. Introduction | |
Cell Line Name: | c-Kit W557_K558del-T670I/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
KIT W557_K558del results in the deletion of 2 amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 557 to 558 (PMID: 12918066). W557_K558del results in constitutive activation of Kit and increased Erk phosphorylation, and leads to increased invasiveness and expression of ETV1 in cell culture (PMID: 25239608, PMID: 26936919). | |
III. Representative Data | |
1. c-Kit W557_K558del-T670I/BaF3 | |
2.Sanger of c-Kit W557_K558del-T670I/BaF3 Figure 2. c-Kit W557_K558del-T670I/BaF3 T670I Figure 3. c-Kit W557_K558del-T670I/BaF3 W557_K558del | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 C-KIT W557_ K558del/T670I (C8). | |
|